We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Intestinal Bacteria Trigger Antibody Class Switching

By Biotechdaily staff writers
Posted on 02 Jul 2007
A recent study has shown how the mucosal cells lining the intestinal walls control the population of beneficial bacteria and may guide developers of drugs designed to stop the growth of gastrointestinal pathogens.

Investigators at Weill Cornell Medical College (New York, NY, USA) studied the mechanism that signaled B cells in the intestinal mucosa to switch to production of IgA2 antibodies. More...
This is an important control mechanism, as IgA2 is more resistant to bacterial proteases than is IgA1. The number of bacteria present is linked to the amount of IgA2.

Their report, published in the June 2007 issue of the journal Immunity, explained that high levels of bacteria in the gut stimulated intestinal epithelial cells to start producing a factor called APRIL (a proliferation-inducing ligand). APRIL, a cytokine-signaling chemical, induced the production of IgA2 in nearby B-cells. The epithelial cells further increased APRIL production by activating dendritic cells via thymic stromal lymphopoietin.

"That is a wholly new finding, since most biologists think of epithelial cells as a barrier cell--not as a highly active player in immune function,” said senior author Dr. Andrea Cerutti, associate professor of patholog4y and laboratory medicine at Weill Cornell Medical College. "Armed with this knowledge, perhaps we can harness the mechanisms we have discovered to ward off more dangerous pathogens that use mucosal surfaces as their point of entry into the body -viruses such as HIV, or Rotavirus, the diarrhea pathogen that kills millions of children in poor countries each year. A better understanding of how the body fights off mucosal pathogens helps us immensely when we try and develop vaccines that target these areas.”


Related Links:
Weill Cornell Medical College

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.